Sveriges mest populära poddar

Oncology Today with Dr Neil Love

Hälsa och motion Medicin

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma

1 tim 2 min•9 augusti 2024

Dr Jesús G Berdeja from the Greco-Hainsworth Tennessee Oncology Centers for Research in Nashville and Dr Thomas Martin from UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco discuss the most relevant new data sets and advances in multiple myeloma, moderated by Dr Neil Love. Produced by Research To Practice.

CME information and select publications here.

Fler avsnitt av Oncology Today with Dr Neil Love

Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

30 apr.•57 min

EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

27 apr.•57 min

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

24 apr.•17 min

Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances

23 apr.•58 min

Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances

20 apr.•59 min

Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

17 apr.•27 min

HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making

16 apr.•1 tim

Metastatic Bladder Cancer — Rapid Case Review Issue 4

15 apr.•28 min

ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy

14 apr.•58 min

Localized Colorectal Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

13 apr.•15 min

Oncology Today with Dr Neil Love med Dr. Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.